Organogenesis (NASDAQ:ORGO) Shares Down 5% – Time to Sell?

Organogenesis (NASDAQ:ORGO)’s share price traded down 5% during trading on Friday . The stock traded as low as $4.90 and last traded at $4.9210. 125,954 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 1,553,580 shares. The stock had previously closed at $5.18.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ORGO shares. BTIG Research reissued a “buy” rating and set a $9.00 price target on shares of Organogenesis in a report on Friday, December 26th. Weiss Ratings restated a “sell (d+)” rating on shares of Organogenesis in a research report on Monday. Finally, Wall Street Zen upgraded Organogenesis from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Organogenesis currently has a consensus rating of “Hold” and a consensus price target of $8.00.

Organogenesis Stock Down 7.1%

The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 2.88. The business’s 50 day moving average price is $5.14 and its 200 day moving average price is $4.66. The firm has a market cap of $610.44 million, a PE ratio of -40.13 and a beta of 1.38.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. The firm had revenue of $150.86 million for the quarter, compared to analyst estimates of $134.10 million. On average, equities research analysts expect that Organogenesis will post -0.07 earnings per share for the current year.

Insider Activity

In related news, Director Glenn H. Nussdorf sold 200,000 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total value of $1,028,000.00. Following the completion of the transaction, the director directly owned 2,565,591 shares of the company’s stock, valued at approximately $13,187,137.74. This represents a 7.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 500,000 shares of company stock valued at $2,620,120 over the last quarter. Insiders own 33.00% of the company’s stock.

Institutional Investors Weigh In On Organogenesis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Creative Planning raised its position in shares of Organogenesis by 8.2% in the third quarter. Creative Planning now owns 38,279 shares of the company’s stock valued at $162,000 after buying an additional 2,887 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Organogenesis by 57.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 14,522 shares of the company’s stock valued at $61,000 after acquiring an additional 5,273 shares in the last quarter. Quarry LP purchased a new stake in Organogenesis during the 3rd quarter valued at about $25,000. State of Alaska Department of Revenue acquired a new stake in Organogenesis in the 3rd quarter valued at about $25,000. Finally, Farther Finance Advisors LLC purchased a new position in Organogenesis in the 2nd quarter worth approximately $35,000. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.